Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Inclusion Criteria: * Age: 18 to 75 * Histologically or cytologically documented gastric adenocarcinoma and esophagus-gastro adenocarcinoma of metastatic or advanced stages with/without measurable tumor according to RECIST standard * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Patients who are expected to live at least 3 months * No prior systemic chemotherapy with advanced stereo- tumor before the recruitment(recidivist/ metastatic without perioperative chemotherapy at least 6m) * No Previous anaphylactic reaction to hormone * Obtaining informed consent * Patients may comply with the study protocol * Laboratory tests: Absolute neutrophil count (ANC) ≥2,000/mm³, Platelet count ≥100,000/mm³, Hemoglobin ≥9.0 g/dL, Serum creatinine≤1.5 x the institutional upper limit of normal (ULN), Creatinine clearance≥50ml/min，Total bilirubin≤1.5 x the institutional upper limit of normal (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 x ULN. In the case of known liver metastasis, ALT and AST（SGOT） ≤1.5 x ULN. Exclusion Criteria: * Active uncontrolled central nervous system metastasis * No adequate organ function or known disease : * myocardial infarction * active heart disease * neuropathy or mental diseases including dementia or epilepsy * blind、deaf、dumb or extremity disability * known infection * active diffuse intravascular coagulation * known infection with hepatitis virus * Pregnant or nursing,fertile patients would not use effective contraception during study treatment * Prior clinically significant gastrointestinal tract disease , that would influence obviously capecitabine to absorb,including the ability to swallow by the attending physician * No other active malignancies except that in complete remission with squamous cell carcinoma in situ of the cervix or anus, completely resected basal cell carcinoma, or no recrudescence for at least 2 year from the time a response was first documented * Having other study medication within 4w * Having radiation therapy or operation within 4w * Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation therapy) (except alopecie and hemoglobin) * Peripheral nerve disease ≥ 2 * Previous anaphylactic reaction to Capecitabine and Paclitaxel or diluents bases * Absence of dihydropyrimidine dehydrogenase * Patients not suitable determined by the attending physician.